指南与共识前列腺癌

孤立性高级别前列腺上皮内瘤变当前管理推荐:重复活检预测价值分析

The current recommendation for the management of isolated high-grade prostatic intraepithelial neoplasia.
指南 / 共识 · BJU Int · 2021-08-25

该研究分析293例既往活检无mpMRI条件下检出孤立性HGPIN、1-3年内重复活检的男性,并设190例无HGPIN对照。结果显示PCa疑诊消失的45例中仅1例(2.2%)检出csPCa;疑诊持续者中既往HGPIN不预测csPCa(OR 1.369,P=0.149),但增加iPCa风险(OR 2.043,P=0.006)。结论:不应仅因既往HGPIN推荐重复前列腺活检。

要点

  • PCa疑诊消失的孤立性HGPIN男性csPCa风险极低(2.2%)。
  • 疑诊持续者中,既往HGPIN不增加csPCa风险(OR 1.369,P=0.149)。
  • 既往HGPIN增加iPCa检出风险(OR 2.043,P=0.006)。

核心结论

  • 孤立性HGPIN且PCa疑诊消失者csPCa风险极低,疑诊持续者csPCa风险不受既往HGPIN影响但iPCa风险增加,不应仅因既往HGPIN推荐重复活检。

研究设计与样本

  • 分析293例既往无mpMRI活检检出孤立性HGPIN、1-3年内重复活检的男性,并设190例无HGPIN等病史对照。
  • 重复活检前行mpMRI及PI-RADS≥3靶向活检和/或系统活检,csPCa定义为Grade Group≥2。

主要发现

  • PCa疑诊消失的45例中检出1例csPCa(2.2%)和1例iPCa。
  • 疑诊持续且既往HGPIN者csPCa检出率34.7%,无HGPIN者为28.4%(P=0.180)。
  • iPCa检出率分别为12.1%和6.3%(P=0.039)。
  • 既往HGPIN不预测csPCa(OR 1.369,95%CI 0.894-2.095;P=0.149),但增加iPCa风险(OR 2.043,95%CI 1.016-4.109;P=0.006)。

关键数值与推荐

  • PCa疑诊定义为持续血清PSA>4 ng/mL和/或直肠指检异常。
  • csPCa定义为Grade Group≥2;mpMRI可疑病灶定义为PI-RADS≥3。

临床怎么用

  • 对孤立性HGPIN且PCa疑诊消失者,可考虑不常规重复活检。
  • 对PCa疑诊持续者,应基于mpMRI及临床情况决策重复活检,而非仅因既往HGPIN。

局限性

  • 既往活检未行mpMRI,结果外推至mpMRI时代需谨慎。
  • 为单中心队列分析,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To analyse the current predictive value of isolated high-grade prostatic intraepithelial neoplasia (HGPIN) for clinically significant prostate cancer (csPCa) detection in repeat biopsies. PATIENTS AND METHODS: A cohort of 293 men with isolated HGPIN detected in previous biopsies performed without multiparametric magnetic resonance imaging (mpMRI), and who underwent repeat biopsy within 1 to 3 years, was analysed. Pre-repeat biopsy mpMRI and guided biopsies to suspicious lesions (Prostate Imaging - Reporting and Data System [PI-RADS] ≥3) and/or and systematic biopsies were performed. Persistent prostate cancer (PCa) suspicion, defined as sustained serum prostate-specific antigen level >4 ng/mL and/or abnormal digital rectal examination, was present in 248 men (84.6%), and was absent in 45 men (15.4%). A control group of 190 men who had no previous HGPIN, atypical small acinar proliferation or HGPIN with atypia who were scheduled to undergo repeat biopsy due to persistent PCa suspicion were also analysed. csPCa was defined as tumours of Grade Group ≥2. RESULTS: In the subset of 45 men with isolated HGPIN, in whom PCa suspicion disappeared, only one csPCa (2.2%) and one insignificant PCa (iPCa) were detected. csPCa was detected in 34.7% of men with persistent PCa suspicion and previous HGPIN, and in 28.4% of those without previous HGPIN (P =0.180). iPCa was detected in 12.1% and 6.3%, respectively (P =0.039). Logistic regression analysis showed that the risk of csPCa detection was not predicted by previous HGPIN: odds ratio (OR) 1.369 (95% confidence interval [CI] 0.894-2.095; P =0.149); however, previous HGPIN increased the risk of iPCa detection: OR 2.043 (95% CI 1.016-4.109; P =0.006). CONCLUSION: The risk of csPCa in men with isolated HGPIN, in whom PCa suspicion disappears, is extremely low. Moreover, in those men in whom PCa suspicion persists, the risk of csPCa is not influenced by the previous finding of HGPIN. However, previous HGPIN increases the risk of iPCa detection. Therefore, repeat prostate biopsy should not be recommended solely because of a previous HGPIN.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Morote J, Schwartzmann I, Celma A, et al. The current recommendation for the management of isolated high-grade prostatic intraepithelial neoplasia. BJU Int. 2021. PMID: 34375498. doi:10.1111/bju.15568

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。